Printer Friendly

ALPHA 1 BIOMEDICALS APPOINTS HAUTALA TO VICE PRESIDENT, CORPORATE DEVELOPMENT

 ALPHA 1 BIOMEDICALS APPOINTS HAUTALA TO VICE PRESIDENT,
 CORPORATE DEVELOPMENT
 WASHINGTON, Jan. 22 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM), today announced it has appointed Judith A. Hautala, Ph.D. to the position of vice president, corporate development.
 Previously, Hautala was vice president, technology development, at Genex Corporation (now a part of Enzon, Inc.) with responsibility for research and development activities and intellectual property matters. She held earlier positions at Genex in both business development and research. Hautala received her Ph.D. degree from Northwestern University and performed postdoctoral research at Memorial Sloan- Kettering Cancer Research Institute in New York.
 Vincent F. Simmon, Ph.D., president and chief executive officer of Alpha 1, said: "Dr. Hautala's extensive scientific, business and patent experience will be of great value as the company moves forward toward obtaining regulatory approval for Thymosin alpha 1 for treating various diseases. Dr. Hautala will become a primary spokesperson for the company to the press and investment community."
 Alpha 1 Biomedicals, Inc., is a Washington-based company engaged in the development of pharmaceutical products. The company's lead product, Thymosin alpha 1, is currently being evaluated in a multi-center Phase III clinical trial in the United States for the treatment of chronic hepatitis B, and is in a single-center Phase III clinical trial in combination with alpha interferon for the treatment of chronic hepatitis C.
 -0- 1/22/92
 /CONTACT: Judith A. Hautala of Alpha 1, 202-628-9898; or Anita Monteith-Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1/
 (ALBM) CO: Alpha 1 Biomedicals, Inc. ST: District of Columbia IN: MTC SU: PER


GK -- NY014 -- 2096 01/22/92 09:08 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 22, 1992
Words:271
Previous Article:RECENT TRENDS PERSIST WITH SLOW RISE IN DOWNTOWN OFFICE VACANCY, FALL IN SUBURBAN; INDUSTRIAL VACANCY RISING
Next Article:BROWNING-FERRIS ANNOUNCES INCOME FOR FIRST QUARTER OF FISCAL 1992
Topics:


Related Articles
BIOGEN APPOINTS LAWRENCE S. DANIELS VICE PRESIDENT-MARKETING AND BUSINESS DEVELOPMENT
MACDONALD NAMED PRESIDENT OF ICN BIOMEDICALS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters